Articles

In his presentation at the World Ophthalmology Congress, Dr Matthew Benz highlighted that the first Phase III trial with microplasmin (TG-MV-006) for the non-surgical treatment of vitreomacular adhesion (VMA) had met its primary endpoint with 27.7% of the 220 microplasmin treated patients achieving resolution of their VMA at 1 month, compared to 13.2% of the 106 patients who received a placebo injection, a highly statistically significant result (p=0.003).

Dr Naveed Shams has been appointed as the new vice president of clinical affairs at Santen Pharmaceutical Co., Ltd.

NCX 434, a new drug candidate form NicOx, is reported to improve oxygen saturation in the eye and preclinical data was recently presented at the Ocular Diseases & Drug Discovery Conference

Developed by US ophthalmologists, the surgical procedure DSAEK (Descemet's Stripping Automated Endothelial Keratoplasty) is increasingly being employed in German eye clinics too.

A team of scientists at UC Irvine (UCI) in California have taken the first step in developing transplant-ready retinas by creating an eight-layer, early-stage retina from human embryonic stem cells.

The European Uveitis Patient Association will present an award to Dr Richard Lee, NIHR clinical lecturer in ophthalmology at the University of Bristol at the forthcoming WOC for his recent research paper

Come and visit the Bausch + Lomb Booth No 16 at the WOC in Berlin to meet the Experts and ask questions. Explore Q2, delivering Quantity and Quality of Vision with the revolutionary Crystalens HD?, the premium accommodating IOL that gives high definition vision at all distances.

Does Google health have a place in practice management

With BluePeak? - blue laser autofluorescence you can noninvasively view the health of the RPE, providing a functional map of RPEphotoreceptor metabolism. BluePeak is available for all SPECTRALIS models.

Haag-Streit and our sister companies – Reliance, Moeller–Wedel, Clement Clarke and John Weiss – are leading players in ophthalmology today – as they have been for more than 150 years.

For nearly two centuries, Moria has been a manufacturer of sophisticated and high quality ophthalmic surgical instrumentation and equipment.

Micro incision surgery for anterior and posterior procedures is featured at the Oertli® booth.

Since introducing the first Laser photocoagulator to ophthalmology in 1970, Lumenis Vision has focused on providing ophthalmologists with innovative laser therapies to preserve and improve the sight of patients worldwide.

According to its press release GBI Research has found that the global ophthalmology market will grow at a moderate rate due to the impact of generic erosion in some markets such as glaucoma and allergic conjunctivitis.

For almost 60 years, the Geuder Group has been developing, manufacturing and distributing ophthalmo-surgical instruments, systems and vitreoretinal liquids.

STAAR Surgical has received CE mark approval for product improvements to its Visian Implantable Collamer Lens (ICL). It also received approval for a Hyperopic Toric ICL which is designed for patients with both hyperopia, as well as astigmatism.

An intact tear film and a good oxygen supply for the cornea are indispensable for contact lens wearing comfort. With the Keratograph TF-Scan software you can analyze the tear film non-invasively.

Experience the revolution in cross linking at booth 15 B 50 where bon Optic will be showing the new Ricrolin TE from the company Sooft.

The Ophthalmology TImes Europe team is looking forward to meeting many readers and customers at the Congress and to bringing you coverage of the event and new developments emerging from it.

Santen is a Japanese R&D focused pharmaceutical company specializing in the development and manufacturing of ophthalmic products.

Recent research by the Optical Express Group says it has revealed that of 32,000 clients surveyed following treatment in 2009, 89 per cent achieved 20/16 vision or better.

According to Novartis the independent DRCR.net study data being presented for the first time in the UK, show that ranibizumab is significantly more effective than laser treatment, the current standard of care, at treating visual impairment due to diabetic macular oedema (DMO).

A small German study of light adjustable lenses (LALs) implanted in 10 eyes in 7 patients has produced positive results, according to the lens's manufacturer, Calhoun Vision.

In a recent press statement Allergan Ltd announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended granting a Marketing Authorisation for OZURDEX (dexamethasone drug delivery system [DEX-DDS]) in the 27 member states of the European Union.

A new type of procedure for correcting short-sightedness could be safer than laser eye surgery, according to a new Cochrane Systematic Review. The study also shows that patients prefer the new procedure, despite there being little difference between the two in terms of improving vision.

Lux Biosciences, Inc. has announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review its New Drug Application (NDA) for Luveniq (oral voclosporin) for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye on June 28, 2010.

Team members of The Surgeless Sultans, The Diffractive Devils, The Chopping Conquerors and The Bursting Buccaneers will be given four minutes to talk about their most challenging cataract/complication cataract case ? with a little help from a video?

People with diabetes have an increased risk of blindness, yet nearly half of the approximately 23 million Americans with diabetes do not get an annual eye exam to detect possible problems. But it appears that cost-effective computerized systems to detect early eye problems related to diabetes can help meet the screening need, University of Iowa analysis shows.

Online research in the Archives of Opthalmology has reported that contact lenses for infants who had undergone surgery for unilateral congenital cataracts resulted in similar visual outcomes for those who received an IOL implant.

The first femtosecond-only method of laser vision correction from Carl Zeiss Meditec is now available for sale outside the United States.